Comparative characterization of the canine normal prostate in intact and castrated animals

Prostate

Volumn 68, Issue 5, 2008, Pages 498-507

  Lai, Chen Li ^a,b   Van Den Ham, René ^a   Van Leenders, Geert ^c   Van Der Lugt, Jaco ^b   Teske, Erik ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Cytokeratins; Morphology; PSA; PSMA; Uroplakin

Indexed keywords

CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 7; HIGH MOLECULAR WEIGHT CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; UROPLAKIN;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOG; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROTEIN EXPRESSION;

ANIMALS; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; DOGS; EPITHELIAL CELLS; KERATIN-18; KERATIN-5; KERATIN-7; MALE; MODELS, ANIMAL; ORCHIECTOMY; PHENOTYPE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN;

EID: 41849091907     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20721     Document Type: Article

References (45)

1. Leav I, Schelling KH, Adams JY, Merk FB, Alroy J. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001;48(3):210-224.
2. Mahapokai W, van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000;3(1):28-33.
3. Johnston SD, Kamolpatana K, Root-Kustritz MV, Johnston GR. Prostatic disorders in the dog. Anim Reprod Sci 2000;60-61:405-415.
4. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD. Clinical and, pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). J Am Vet Med Assoc 1991;199(11):1623-1630.
5. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases. Prostate 2000;45(2):173-183.
6. Gottfried HW, Brandle E, Hefty R, Mattfeldt T, Badura W, Vogel U, Hautmann RE. Laser therapy in dogs and humans - is there a difference? Br J Urol 1997;79(3):385-388.
7. Furr BJ. The development of Casodex (bicalutamide): Preclinical studies. Eur Urol 1996;29 (Suppl 2):83-95.
8. Mahapokai W, Xue Y, van Garderen E, van Sluijs FJ, Mol JA, Schalken JA. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. Prostate 2000;44(1):40-48.
9. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80(8):1251-1258.
10. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ. Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998;36(1):64-67.
11. Wang Y, Hayward SW, Cao M, Thayer KA, Cunha GR. Cell differentiation lineage in the prostate. Differentiation 2001;68(4-5):270-279.
12. Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA. Identification of intermediate cell types by keratin expression in the developing human prostate. [erratum appeared in Prostate 1998;35(2):156]. Prostate 1998;34(4):292-301.
13. Mulders TM, Bruning PF, Bonfrer JM. Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker. Eur J Surg Oncol 1990;16(1):37-41.
14. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3(1):81-85.
15. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol 1995;147(5):1383-1397.
16. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 2002;33(11):1136-1140.
17. LeRoy BE, Nadella MV, Toribio RE, Leav I, Rosol TJ. Canine prostate carcinomas express markers of urothelial and prostatic differentiation. Vet Pathol 2004;41(2):131-140.
18. Espinosa de los Monteros A, Fernandez A, Millan MY, Rodriguez F, Herraez P, Martin de las Mulas J. Coordinate expression of cytokeratins 7 and 20 in feline and canine carcinomas. Vet Patho 1999;36(3):179-190.
19. Grieco V, Patton V, Romussi S, Finazzi M. Cytokeratin and vimentin expression in normal and neoplastic canine prostate. J Comp Pathol 2003;129(1):78-84.
20. Landry F, Chapdelaine A, Begin LR, Chevalier S. Phosphotyrosine antibodies preferentially react with basal epithelial cells in the dog prostate. J Urol 1996;155(1):386-390.
21. Sorenmo KU, Goldschimdt M, Shofer F, Goldkamp C, Ferracone J. Immunohistochemical characterization of canine prostatic carcinoma and correlation with castration status and castration time. Vet Comp Oncol 2003;1(1):48-56.
22. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001;46(1):2-10.
23. Teske E, Naan EC, van Dijk EM, Van Garderen E, Schalken JA. Canine prostate carcinoma: Epidemiological evidence of an increased risk in castrated dogs. Mol Cell Endocrinol 2002;197(1-2):251-255.
24. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50(4):203-215.
25. McNeal JE. The zonal anatomy of the prostate. Prostate 1981;2(1):35-49.
26. McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol 1968;49(3):347-357.
27. McNeal JE. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound CT 1988;9(5):329-334.
28. Hornbuckle WE, MacCoy DM, Allan GS, Gunther R. Prostatic disease in the dog. Cornell Vet 1978;68 (Suppl 7):284-305.
29. Mahapokai WS. Hormonally-induced benign prostatic hyperplasia in the dog. Thesis. Utrecht: Printpartners Ipskamp, Enschede; 2000.
30. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12(8):619-633.
31. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
32. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001;46(1):2-10.
33. Bell FW, Klausner JS, Hayden DW, Lund EM, Liebenstein BB, Feeney DA, Johnston SD, Shivers JL, Ewing CM, Isaacs WB. Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. J Vet Intern Med 1995;9(3):149-153.
34. Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res 1995;55(11):2455-2462.
35. Olsson AY, Lilja H, Lundwall A. Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. Genomics 2004;84(1):147-156.
36. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001;46(1):2-10.
37. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter RE, Bander NH, Rajasekaran AK. Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate 2003;55(1):9-19.
38. Aggarwal S, Ricklis RM, Williams SA, Denmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate 2006;66(9):903-910.
39. Chen-Li Lai, van den Ham R, van Leenders G, van der Lugt J, Mol JA, Teske E. Histopathological and immunohistochemical characterization of canine prostate cancer. Prostate (accepted).
40. van den Ham R, Lai C-L, van Wolferen ME, van Leenen D, Teske E, Mol JA. Canine and human prostate cancer derived cell lines share aberrant signaling pathways. (submitted).
41. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR. Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 1981;48(5):1229-1232.
42. Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwege P, De Nayer P, Van Cangh P, Tombal B. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value? Clin Cancer Res 2000;6(10):4049-4054.
43. Colombel M, Olsson CA, Ng PY, Buttyan R. Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 1992;52(16):4313-4319.
44. Slack JM. Stem cells in epithelial tissues. Science 2000;287(5457):1431- 1433.
45. De Rooij DG, Van Dissel-Emiliani FM, Van Pelt AM. Regulation of spermatogonial proliferation. Ann N Y Acad Sci 1989;564:140-153.